AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Akebia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.68+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $183.36M
- P/E (TTM)
- –
- Dividend yield
- –
Akebia Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $46.77M | $51.99M | $54.29M | $56.79M | $60.46M | $55.79M | $44.37M | $35.59M | $41.21M | $31.01M | $53.23M | $40.12M | 95.2% | -22.7% |
| Auryxia | $25.46M | $36.19M | $48.14M | $42.47M | $47.18M | $43.76M | $44.37M | $35.59M | $41.21M | $31.01M | – | – | 51.8% | -46.0% |
| Vafseo | $21.30M | $15.80M | $6.16M | $14.32M | $13.28M | $12.03M | $0 | $0 | $0 | $0 | – | – | 43.4% | +60.4% |
| License, collaboration and other revenue | $2.36M | $1.55M | $3.33M | $1.98M | $2.01M | $1.55M | $2.13M | $1.84M | $2.44M | $1.60M | $2.96M | $1.93M | 4.8% | +17.5% |
| Royalty payments | $100.00K | – | – | – | $0 | – | – | – | – | – | – | – | 0.2% | – |
By region
From the segment and revenue-disaggregation notes of Akebia Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.